The medication is used for women after menopause who still have their uterus. The primary therapeutic uses for this medication include the Management of Symptoms of Oestrogen Deficiency and Support for Bone Health.

Symptom Management and Therapeutic Scope

Sequidot is commonly used to help manage symptoms related to systemic imbalance occurring after menopause, such as intense hot flushes and night sweats, which can become disruptive and interfere with daily functioning. By easing these vasomotor symptoms, it may also assist with managing associated sleep disturbances and irritability. Additionally, it is relevant for easing localized discomforts like vaginal dryness.

Applied in settings where additional symptomatic support is needed, this medication provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods. It is also indicated for the prevention of osteoporosis in women who are at high risk of fracture.

“This medication is applied in scenarios where additional management of discomfort is required, and may assist with maintaining functional stability during symptom fluctuations.”

Quick Fact: Support for Hot Flushes Sequidot is commonly used to help manage the frequency and intensity of hot flushes and night sweats, the two most common and disruptive symptoms related to systemic imbalance after menopause.

Regulatory References

1. Official Product Information

Who can and cannot use Sequidot?

The use of Sequidot is strictly determined by regulatory rules that define the eligible population and absolute exclusions.

Eligible and Target Populations

Sequidot is officially intended for post-menopausal women who are typically more than one year post-menopause and require Hormone Replacement Therapy. The medicine's combined sequential formulation is specifically required for women who have an intact uterus.

Absolute Contraindications (Must Not Use)

Sequidot is contraindicated and must not be used in patients with a known, past, or suspected history of breast cancer or other oestrogen-dependent malignant tumours. Use is also prohibited in the presence of active or recent venous thromboembolism (DVT or PE) or arterial thromboembolic disease (e.g., stroke), as well as acute liver disease or undiagnosed genital bleeding.

Conditional Use and Restrictions

Specific patient groups require special care and close supervision. This includes women with hypertension, diabetes mellitus, uterine fibroids (leiomyoma), or mild liver function impairment. Sequidot is not indicated for use in children and is contraindicated during pregnancy and lactation. The official regulatory experience of treating women older than 65 years is limited.

This section summarizes officially documented drug and substance interactions for Sequidot, as established in government regulatory product information.

Contraindicated Combinations and Exposure Modification

Classification	Interacting Agents	Official Interaction Basis
Contraindicated	Specific Hepatitis C regimens (e.g., those containing Ombitasvir, Paritaprevir, and Dasabuvir co-administered with Ritonavir).	Prohibited due to the documented risk of transaminase (ALT) elevation when combined with estrogens.
Exposure Reduced	Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin), and the herbal product St. John's Wort.	Accelerate the metabolism and clearance of both Estradiol and Norethisteron, documented to reduce the hormones' systemic exposure.
Exposure Increased	Strong CYP3A4 Inhibitors (e.g., Ketoconazole).	Documented to decrease the clearance of the hormones, potentially increasing their systemic exposure.

Other Documented Interactions

The active components are also documented to influence the clearance of other drugs. Sequidot's hormones are known to accelerate the metabolism of Lamotrigine, which results in a reduction of its plasma concentration. Additionally, women on Thyroid Hormone Replacement therapy may require dosage adjustments, as the hormones can affect the levels of thyroid-binding globulin.

Regulatory documents note that the co-administration of Grapefruit Juice may also interact by inhibiting hormone metabolism.

Sequidot functions as a partial agonist at the central Dopamine D2 receptor (D2). This interaction modulates the activity of the dopaminergic signaling pathway in specific regions of the central nervous system. As a partial agonist, Sequidot binds to the D2 receptor and produces a sub-maximal response compared to the natural ligand, dopamine. This allows the molecule to exert an adaptive influence, dampening excessive dopamine signaling where needed, while augmenting deficient signaling in other scenarios, depending on the baseline concentration of dopamine at the synapse.

The binding initiates an intracellular cascade that involves G-protein coupling. Specifically, the activated D2 receptor inhibits adenylyl cyclase (AC), leading to a decrease in the intracellular concentration of cyclic adenosine monophosphate (cAMP). This reduction in cAMP activity modulates downstream protein kinase A (PKA) signaling.

At a system level, this balanced modulation of dopamine activity contributes to a normalization of neurotransmitter flow in key brain circuits, including the mesolimbic and mesocortical pathways. This rebalancing acts to stabilize the physiological processes linked to affective and cognitive regulation.

How to Use Sequidot: Administration Overview

Sequidot is a transdermal patch administered via a structured continuous sequential regimen for Hormone Replacement Therapy (HRT). The standard treatment follows a precise 28-day cycle with twice-weekly patch changes, ensuring a consistent pattern of hormone delivery.

---

Administration Scope

Instruction Entity	Instruction
Route of Administration	Transdermal (absorption through the skin).
Dosing Schedule	28-day continuous sequential regimen. Phase I (Estradiol-only, 50 micrograms/24 h) for the first 14 days, followed immediately by Phase II (Estradiol 50 micrograms/24 h and Norethisterone Acetate 250 micrograms/24 h) for the remaining 14 days.
Frequency	Twice Weekly (a new patch is applied every 3 to 4 days).
Application Site	Applied to the abdomen (lower stomach area), below the waistline, and never on or near the breasts.
Skin Condition	The application site must be clean, dry, and non-oily, free from irritation or cuts.
Missed Dose Rule	If application is forgotten, a new patch is applied as soon as possible, and the original schedule is then resumed.

---

Procedural Structure

The usage protocol is defined by the following sequence, designed to maintain the required hormone pattern:

1. Begin the 28-day cycle by applying one Phase I patch (Estradiol-only) to the abdomen.
2. Change the Phase I patch every 3 to 4 days for the first 14 days, ensuring the application site is rotated each time.
3. Immediately switch to applying the Phase II patch (combination), changing it every 3 to 4 days for the remaining 14 days of the cycle.
4. After removing the last Phase II patch, the next 28-day cycle is started immediately with a new Phase I patch.

This continuous sequential application protocol governs the precise delivery of both the estrogen and progestogen components throughout the entire treatment, in accordance with the product's standard labeling.

Clinical studies supporting Sequidot, a transdermal hormone replacement therapy (HRT) containing estradiol and norethisterone acetate (NETA), have focused on its efficacy and safety in managing postmenopausal symptoms.

Efficacy in Symptom Relief

Clinical trials have demonstrated that the continuous release of hormones from the transdermal patch effectively reduces common moderate-to-severe vasomotor symptoms, such as hot flashes and night sweats. The fixed combination of an estrogen (estradiol) and a progestogen (NETA) is specifically indicated for women with an intact uterus. The estrogen component addresses the symptoms of estrogen deficiency, while the progestogen is included to counteract the proliferative effect of unopposed estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia and carcinoma.

Safety and Risk Profile

The safety profile of Sequidot is consistent with that of combination HRT. A key focus of clinical evidence involves assessing the balance of benefits and risks, particularly concerning cardiovascular events and certain cancers.

• Endometrial Protection: The sequential-combined regimen, where NETA is added for a portion of the cycle, has been clinically shown to protect the endometrium. The progestogen exposure prevents the excessive growth of the uterine lining induced by estrogen.
• Thromboembolic Risk: As with all systemic HRT, use of Sequidot is associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, and stroke. This risk is considered relative to non-use and depends on individual patient risk factors and duration of therapy.
• Breast Cancer Risk: Clinical evidence, including data from large-scale observational and randomized trials of combined HRT, suggests a small increase in the risk of breast cancer with prolonged use, generally becoming apparent after several years of treatment.

Regulators emphasize that HRT should be used at the lowest effective dose for the shortest duration necessary to achieve treatment goals, and that the long-term use of combined estrogen-progestogen therapy requires periodic risk reassessment.

Common questions about Sequidot (FAQ)

---

Q: Are there any long-term effects of using Sequidot?

A: Official documents focus on the balance of benefits versus risks for long-term use. Regulatory documents indicate that the use of combined Hormone Replacement Therapy is associated with documented increased risks of conditions such as Venous Thromboembolism (VTE), stroke, and breast cancer when used for prolonged periods. Regulatory guidelines for this class of medicine state that therapy should be managed using the lowest effective dose for the shortest duration necessary, with regular reassessment of risks and benefits by a healthcare professional.

---

Q: Why is Sequidot described as a 'sequential' treatment?

A: Sequidot is classified as a continuous sequential treatment because the two hormones, estradiol and norethisterone, are delivered in a specific order. The progestogen component, norethisterone, is added sequentially for the last 14 days of the 28-day cycle. This sequential addition is mandatory for women with an intact uterus, as it helps counteract the effects of unopposed estrogen and reduces the risk of endometrial hyperplasia (thickening of the uterine lining).

---

Q: What kind of studies have been done on Sequidot?

A: Clinical trials have primarily focused on establishing the medicine's efficacy in providing relief from moderate-to-severe vasomotor symptoms, such as hot flashes and night sweats. Studies also examine the overall safety profile, including the benefits of endometrial protection provided by the progestogen component, and the documented risks regarding venous thromboembolism (VTE) and breast cancer.

---

Q: Why are people talking about Sequidot compared to taking pills?

A: Sequidot is a transdermal patch, meaning it delivers hormones through the skin rather than being swallowed as a pill. Official product information notes that this route of administration bypasses the gastrointestinal system and the initial metabolism by the liver. This physiological difference is a key distinction between transdermal and oral hormone preparations.

---

Q: How long can I continue to use Sequidot?

A: Regulatory guidance states that Hormone Replacement Therapy (HRT) should be used at the lowest effective dose for the shortest duration necessary to effectively manage postmenopausal symptoms. The continuation of treatment is subject to regular periodic risk reassessment by a healthcare professional, as stipulated in the official instructions.

---

Q: What is the difference between Sequidot and a continuous patch?

A: Sequidot is classified as a continuous sequential combination patch. This means the estrogen component is delivered continuously throughout the cycle, but the progestogen component is added sequentially for only the last 14 days of the 28-day cycle. This differs from a continuous combined patch, which delivers both hormones simultaneously every day of the cycle.

---

Q: Is it possible to be allergic to the adhesive on the Sequidot patch?

A: Official documents list local application site reactions, such as redness, itching, or irritation, as a Very Common side effect of the patch. General allergic reactions are listed as uncommon to very rare. This indicates the skin reaction is a frequent occurrence, though regulatory documents do not specify whether the cause is the adhesive or another patch component.

---

Q: Why do some people experience localized reactions to the Sequidot patch?

A: Official regulatory information indicates that local application site reactions (including redness and irritation) are classified as a Very Common side effect. This means the reaction is documented to occur in more than 1 in 10 users.

---

Q: Can Sequidot be prescribed for women who have had a hysterectomy?

A: Official documents state that the combined sequential formulation of Sequidot is specifically indicated for women who have an intact uterus. Official information indicates that for women who have had a hysterectomy, healthcare providers typically consider the use of estrogen-only preparations, as the progestogen component is no longer needed for endometrial protection.

---

Q: Is Sequidot a birth control patch or something else?

A: Sequidot is classified by regulatory bodies as a Hormone Replacement Therapy (HRT) intended for the management of postmenopausal symptoms. Official product information states that it is not intended for use as a contraceptive (birth control) and does not protect against pregnancy.

---

Q: Do I need to change my diet while using Sequidot?

A: Regulatory documents note that the co-administration of Grapefruit Juice may interact by inhibiting hormone metabolism, which could potentially affect the level of hormones in the body. Beyond this specific note, no general dietary restrictions are mandated in the official labeling for Sequidot.

---

Q: Is Sequidot safe to use if I smoke?

A: Regulatory documents indicate that the serious risks associated with smoking, specifically thromboembolic events, are generally a greater concern with oral combined HRT products. However, smoking remains a factor that is evaluated by the healthcare professional.

---

Q: What should I do if the Sequidot patch falls off?

A: If the patch detaches, the same patch may be re-applied to another clean, dry area of the skin. If reapplication is not possible, a new patch should be applied. Official instructions specify that regardless of reapplication or using a new patch, the patient should continue to follow the original treatment schedule, replacing the patch on the usual change days.

---

Q: Can I go swimming or exercise vigorously while wearing Sequidot?

A: Regulatory warnings indicate that care should be taken during strenuous physical activity or when wearing tight-fitting clothing. This caution is noted because excessive sweating or friction can potentially cause the patch to loosen, rub off, or detach from the skin.

---

Q: Is Sequidot available over the counter, or is it prescription only?

A: According to official regulatory documents, Sequidot is classified as a prescription-only medicine. It cannot be legally dispensed or purchased without a valid prescription.

---

Q: Is there any research evidence about Sequidot and bone health?

A: Official product indications include the prevention of osteoporosis in postmenopausal women. This indication is specifically for women who are considered to be at high risk of future fractures and who are intolerant of, or contraindicated for, other medicinal products approved for prevention.

---

Q: If I have allergies, can I still use the Sequidot patch?

A: The medicine is listed as contraindicated (not to be used) in official documents for individuals with a known hypersensitivity (severe allergy) to the active ingredients or to any component of the patch.

---

Q: What is the experience like for users switching from oral medicine to Sequidot?

A: Official product information specifies the protocol for starting Sequidot when switching from other HRT types. Women who are already using a continuous combined therapy may switch directly to Sequidot. Women on cyclical or sequential therapy are instructed to switch after completing the current treatment cycle, beginning Sequidot on the first day of the expected withdrawal bleeding.

---

Q: Does the Sequidot patch leave a mark on the skin?

A: Regulatory guidance notes that a sticky substance may remain on the skin after the patch is removed. If residue occurs, information suggests that it can often be cleared with the gentle use of an oil or lotion approximately 15 minutes after patch removal.

---

Q: Can sun exposure affect how Sequidot works?

A: Official regulatory information instructs that once the Sequidot patch is applied to the skin, it should not be exposed to sunlight for any prolonged periods of time.

---

Q: What are the official sources describing Sequidot's safety profile?

A: Official safety information is contained in documents published by national and intergovernmental regulatory bodies. These key sources include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other government health authorities.

---

Q: Is Sequidot proven to be non-addictive?

A: Sequidot is classified as a Hormone Replacement Therapy (HRT). Official regulatory agencies do not classify this medicine as a controlled substance with the potential for abuse or dependence.

---

Q: Are there any limitations on who can use Sequidot based on family medical history?

A: Regulatory guidance states that a family history of certain conditions, such as breast cancer, is not typically listed as an absolute contraindication for use. Regulatory guidance on HRT focuses heavily on the patient's own medical history.

---

Q: What are the general expectations about discontinuing Sequidot?

A: Regulatory information states that interrupting or stopping the medicine may increase the likelihood of the recurrence of postmenopausal symptoms, such as hot flashes. It may also lead to breakthrough bleeding or spotting.

---

Q: Does Sequidot affect cholesterol levels?

A: Regulatory documents caution that the estrogen component in Sequidot can affect lipid changes in the body. There are documented warnings about potential elevations in triglyceride levels, particularly for women who have pre-existing high triglyceride levels.

Sequidot must be stored according to regulatory labeling to maintain product integrity and ensure safety.

Storage Requirements

The medicine must be stored in a cool, dry place where the temperature does not exceed 25 C. The patches must be kept in their original sealed pouch and outer container until the time of use to protect them from moisture and light. It is prohibited to store the medicine in high-moisture areas, such as a bathroom, or expose it to excessive heat, such as in a car or on a window sill.

Disposal Instructions

To dispose of a used patch, it must be folded in half immediately after removal so the sticky adhesive side adheres to itself. All patches, both used and unused, must be kept out of the sight and reach of children and pets. Unused or expired patches should be returned to a pharmacist for proper disposal, and used patches must not be flushed down the toilet or disposed of in wastewater.